Research Pipeline

Drug development programs

Small Pharma’s pipeline of short-acting psychedelic programs is in development to address mental health indications where there is significant unmet need.

research pipeline

Our Pipeline

Our current progress across our R&D programs

The investigational product candidates listed here are not approved by the United States Food and Drug Administration (FDA), the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) or European Medicines Agency (EMA) and the safety and effectiveness is yet to be established.

SPL026
Injectable DMT

Exploring DMT fumarate SPL026 with supportive therapy to treat Major Depressive Disorder. Small Pharma was awarded an Innovation Passport designation by the MHRA for this program, providing access to the ILAP (Innovative Licensing & Access Pathway) which aims to accelerate time to market.

SPL028
Deuterated DMT

An injectable formulation of deuterated DMT designed to deliver a more prolonged psychedelic experience.

SPL029
Oral tryptamine series

An oral formulation of a tryptamine to offer an alternative way to deliver the treatment to patients in clinic. 

Pipeline Programs

Our current pipeline programs are based on psychedelic tryptamines including the short-acting compound DMT or N,N, dimethyltryptamine – a naturally occurring psychoactive molecule. [1] Amongst the family of tryptamine structures is serotonin. Other so-called “classical” psychedelics, such as psilocybin and 5-MeO-DMT, also have tryptamine-derived chemical structures. DMT targets a number of receptors in the brain, notably the 5-HT2A serotonin receptor. [2] Small Pharma is manufacturing synthetic drug candidates.

Partners

About Small Pharma

We’re a biotechnology company researching and developing short-acting psychedelics with supportive therapy for mental health conditions.

Register for Company Updates


    Corporate Presentation

    Follow us: